Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 29, 2026

Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum

View original at seekingalpha.com
Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum Earnings Call Insights: Valley National Bancorp (VLY) Q4 2025 MANAGEMENT VIEW * Ira Robbins, President, CEO & Chairman, highlighted "record earnings in the fourth quarter of 2025 with net income of approximately $195…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If no rate cuts occur, there would be approximately 0.5% to 1% headwind from net interest income

    80% confidence
  • Management is conservatively assuming modest spread compression in the net interest income forecast

    80% confidence
  • Core deposits grew nearly $4 billion or 9% year-over-year

    80% confidence
  • Adjusted return on average assets of 1.14% represents the highest level since Q4 2022

    80% confidence
  • Valley National achieved record earnings in Q4 2025 with net income of approximately $195 million or $0.33 per diluted share

    80% confidence
  • Loan growth was strong, diverse and tightly aligned with relationship-focused strategy, with commercial real estate loans growing sequentially for the first time since Q2 2024

    80% confidence
  • Management feels very strong about the lift off in the beginning of 2026 with significant tailwinds

    80% confidence
  • Valley National exceeded expectations across all major metrics by year-end while strengthening capital and liquidity positions

    80% confidence
  • First quarter tends to be somewhat softer as a result of lower day count, elevated payroll taxes within operating expenses and seasonal headwinds on both sides of the balance sheet

    80% confidence
  • Valley National expects mid-single-digit loan growth for 2026 supported by roughly 10% C&I growth, low single-digit CRE growth and mid-single-digit consumer and residential growth

    80% confidence
  • Recent additions to teams in New Jersey, California and Florida have already generated loan and deposit activity

    80% confidence
  • If the economy stays in the current situation, the trend of classified asset improvement is expected to continue in 2026 and into 2027

    80% confidence
  • Net interest income will grow between 11% and 13% in 2026

    80% confidence
  • Benefits between now and end of 2026 will be fairly balanced between loan and deposit sides of balance sheet, with $1.8 billion of fixed rate loans maturing in 2026 at around 4.7% coming back on 150 to 200 basis points higher

    80% confidence
  • Medium and late-stage loan pipelines are exceptionally strong, up over $1 billion or nearly 70% from just a year ago

    80% confidence
  • Strategic priorities for 2026 include igniting small business sales efforts, improving branch productivity and exploring new growth-oriented deposit niches

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum — Source | Via News | ViaNews Market